Evidence map›Paper›PMID 34885179›Full record

ReviewCancers2021

Oncologic Impact and Safety of Pre-Operative Radiotherapy in Localized Prostate and Bladder Cancer: A Comprehensive Review from the Cancerology Committee of the Association Française d'Urologie.

Paul Sargos, Stéphane Supiot, Gilles Créhange, Gaëlle Fromont-Hankard, Eric Barret, Jean-Baptiste Beauval, Laurent Brureau, Charles Dariane, Gaëlle Fiard, Mathieu Gauthé and 7 more

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 1 country.

Paul SargosDepartment of Radiotherapy, Institut Bergonié, 33000 Bordeaux, France.
Stéphane SupiotDepartment of Radiotherapy, Insitut de Cancérologie de l'Ouest, 44800 St-Herblain, France.ORCID 0000-0003-2094-1708
Gilles CréhangeDepartment of Radiotherapy, Institut Curie, 75005 Paris, France.
Gaëlle Fromont-HankardDepartment of Pathology, CHRU Tours, 37000 Tours, France.
Eric BarretDepartment of Urology, Institut Mutualiste Montsouris, 75014 Paris, France.
Jean-Baptiste BeauvalDepartment of Urology, La Croix du Sud Hôpital, 31130 Quint Fonsegrives, France.
Laurent BrureauDepartment of Urology, CHU de Pointe-à-Pitre, University of Antilles, University of Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, 97110 Pointe-à-Pitre, France.
Charles DarianeDepartment of Urology, Hôpital Européen Georges-Pompidou, APHP, Paris-Paris University-U1151 Inserm-INEM, Necker, 75015 Paris, France.
Gaëlle FiardDepartment of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, 38000 Grenoble, France.ORCID 0000-0003-3049-5318
Mathieu GauthéUnité de Recherche Clinique en Économie de la Santé, CRESS METHODS INSERM UMR 1153, 75000 Paris, France.
Romain MathieuDepartment of Urology, CHU Rennes, 35033 Rennes, France.
Guilhem RoubaudDepartment of Medical Oncology, Institut Bergonié, 33000 Bordeaux, France.
Alain RuffionService d'Urologie Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69002 Lyon, France.
Raphaële Renard-PennaDepartment of Radiology, Sorbonne University, AP-HP, Pitie-Salpetriere Hospital, 75013 Paris, France.
Yann NeuzilletDepartment of Urology, Hôpital Foch, 92151 Suresnes, France.
Morgan RouprêtDepartment of Urology, Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, 75013 Paris, France.
Guillaume PloussardDepartment of Urology, La Croix du Sud Hôpital, 31130 Quint Fonsegrives, France.ORCID 0000-0002-6004-2152
Inserm · FRHôpital de la Croix-Rousse · FRInstitut Bergonié · FRSorbonne Université · FRCentre Hospitalier Universitaire de Rennes · FRCentre Hospitalier Universitaire de Tours · FRHôpital Foch · FRInstitut Curie · FRInstitut de Cancérologie de l'Ouest · FRInstitute Mutualiste Montsouris · FRInstitut polytechnique de Grenoble · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preoperative radiotherapy (RT) is commonly used for the treatment of various malignancies, including sarcomas, rectal, and gynaecological cancers, but it is preferentially used as a competitive treatment to radical surgery in uro-oncology or as a salvage procedure in cases of local recurrence. Nevertheless, preoperative RT represents an attractive strategy to prevent from intraoperative tumor seeding in the operative field, to sterilize microscopic extension outside the organ, and to enhance the pathological and/or imaging tumor response rate. Several clinical works support this research field in uro-oncology. In this review article, we summarized the oncologic impact and safety of preoperative RT in localized prostate and muscle-invasive bladder cancer. Preliminary studies suggest that both modalities can be complementary as initial primary tumor treatments and that a pre-operative radiotherapy strategy could be beneficial in a well-defined population of patients who are at a very high-risk of local relapse. Future prospective trials are warranted to evaluate the oncologic benefit of such a combination of local treatments in addition to new life-prolonging systemic therapies, such as immunotherapy, and new generation hormone therapies. Moreover, the safety and the feasibility of salvage surgical procedures due to non-response or local recurrence after pelvic RT remain poorly evaluated in that context.

Indexed as

bladder cancerneoadjuvantpreoperativeprostate cancerradiotherapy

Identifiers

PMID34885179
PMCPMC8656987
OpenAlexW3215813494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.